ATEA PHARMACEUTICALS INC's ticker is AVIR and the CUSIP is 04683R106. A total of 128 filers reported holding ATEA PHARMACEUTICALS INC in Q2 2022. The put-call ratio across all filers is 0.09 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,809,564 | -67.8% | 603,188 | -59.9% | 0.00% | -100.0% |
| Q2 2023 | $5,623,026 | +3.8% | 1,503,483 | -7.0% | 0.00% | 0.0% |
| Q1 2023 | $5,414,967 | +63.5% | 1,616,408 | +134.7% | 0.00% | 0.0% |
| Q4 2022 | $3,312,094 | +18.0% | 688,585 | +39.5% | 0.00% | – |
| Q3 2022 | $2,808,000 | -19.9% | 493,504 | -0.1% | 0.00% | – |
| Q2 2022 | $3,506,000 | -73.8% | 493,854 | -73.4% | 0.00% | -100.0% |
| Q1 2022 | $13,407,000 | -32.3% | 1,856,925 | -16.2% | 0.00% | -50.0% |
| Q4 2021 | $19,818,000 | +69.7% | 2,216,832 | +565.8% | 0.00% | +33.3% |
| Q3 2021 | $11,675,000 | +158.2% | 332,982 | +58.2% | 0.00% | +200.0% |
| Q2 2021 | $4,521,000 | +275.2% | 210,481 | +978.6% | 0.00% | – |
| Q1 2021 | $1,205,000 | -82.9% | 19,514 | -88.4% | 0.00% | -100.0% |
| Q4 2020 | $7,028,000 | – | 168,205 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Bain Capital Life Sciences Investors, LLC | 2,485,638 | $17,648,000 | 2.07% |
| EcoR1 Capital, LLC | 6,340,639 | $45,019,000 | 1.55% |
| CM Management, LLC | 200,000 | $1,420,000 | 1.51% |
| K2 PRINCIPAL FUND, L.P. | 1,606,059 | $11,403,000 | 1.26% |
| Cormorant Asset Management, LP | 1,547,181 | $10,985,000 | 0.83% |
| Privium Fund Management (UK) Ltd | 61,284 | $435,000 | 0.49% |
| Atom Investors LP | 30,911 | $219,000 | 0.10% |
| FEDERATED HERMES, INC. | 3,588,131 | $25,476,000 | 0.07% |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC | 347,612 | $2,468,000 | 0.06% |
| BALYASNY ASSET MANAGEMENT L.P. | 1,799,507 | $12,777,000 | 0.04% |